A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Inclusion Criteria:

- Type 2 diabetes mellitus and be at least 30 years of age

- Moderate or severe chronic renal insufficiency or end stage renal disease on dialysis

- Meet one of the following criteria:

1. is currently not on an antihyperglycemic agent (AHA) and has A1C >=7% and <=10%
at screening

2. is currently on a single oral AHA or low-dose dual oral combination AHA and has
A1C >=6.5% and <=9% at screening

3. is currently on a stable insulin regimen (>= 15 U/day) for >= 10 weeks, with no
oral AHA, and has A1C >=7.5% and <=10% and FPG >130 mg/dL at screening

- (1) Male; (2) female not of reproductive potential; or (3) female of reproductive
potential who agrees to remain abstinent or use alone or in conjunction with their
partner 2 methods of contraception to prevent pregnancy during the study and for 28
days after the last dose of study drug

Exclusion Criteria:

- History of type 1 diabetes mellitus or a history of ketoacidosis

- Treated with any incretin mimetic or thiazolidinedione (TZD) within 12 weeks prior to
screening or with MK-3102 at any time prior to study participation

- History of hypersensitivity to a dipeptidyl peptidase IV (DPP-4) inhibitor

- History of intolerance or hypersensitivity to glipizide or insulin glargine or any
contraindication to glipizide or insulin glargine

- On a weight loss program and is not in the maintenance phase, or has been on a weight
loss medication in the past 6 months, or has undergone bariatric surgery within 12
months prior to study participation

- Undergone a surgical procedure within 4 weeks prior to screening or has planned major
surgery during the trial

- On or likely to require treatment for >=2 consecutive weeks or repeated courses of
corticosteroids (note: inhaled, nasal or topical corticosteroids are permitted)

- Currently being treated for hyperthyroidism or is on thyroid replacement therapy and
has not been on a stable dose for at least 6 weeks

- If on dialysis, does not regularly adhere to dialysis schedule

- Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class IV

- Medical history of active liver disease (other than non-alcoholic hepatic steatosis),
including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic
gallbladder disease

- Human immunodeficiency virus (HIV)

- New or worsening coronary heart disease, congestive heart failure, myocardial
infarction, unstable angina, coronary artery intervention, stroke, or transient
ischemic neurological disorder within the past 3 months

- Poorly controlled hypertension

- Severe active peripheral vascular disease

- History of malignancy <=5 years prior to study participation, except for adequately
treated basal cell or squamous cell skin cancer, or in situ cervical cancer

- Clinically important hematological disorder (such as aplastic anemia,
myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

- Positive pregnancy test

- Pregnant or breast-feeding, or is expecting to conceive or donate eggs during the
trial, including 28 days following the last dose of study drug

- User of recreational or illicit drugs or has had a recent history of drug abuse or
routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or
engages in binge drinking